Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
fda
9
×
life sciences
national
9
×
national blog main
san francisco top stories
clinical trials
national top stories
new york top stories
san francisco blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
eli lilly
amgen
cancer immunotherapy
drugs
europe top stories
food and drug administration
investing
nonalcoholic steatohepatitis
startups
teva pharmaceutical
What
drug
9
×
fda
approval
medicine
new
roundup
amgen
annual
approved
attention
bio
biotech
cancer
class
companies
developed
drugs
europe
home
marketing
meeting
migraine
nod
oral
patients
potential
prices
won
afternoon
ahead
alzheimer’s
ambien
american
amgen’s
anticipated
arguments
asco
assessed
atrophy
attendees
Language
unset
Current search:
fda
×
biotech
×
national
×
drug
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details